Studies have found that in mice constructed with glycation-deficient liver receptor homolog 1 (LRH-1) mutation, the expression level of OSBPL3 in liver is significantly increased, which promotes the incidence and development of MASLD.[10,11] This indicates that OSBPL3 is indeed involved in the incidence and development of MASLD and can participate in the treatment of MASLD disease progression. The gene discussed is OSBPL3; the disease is metabolic dysfunction-associated steatotic liver disease.